Piramal Pharma (BOM:543635) Gross-Profit-to-Asset % : 45.90% (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Piramal Pharma's annualized Gross Profit for the quarter that ended in Mar. 2025 was ₹71,964 Mil. Piramal Pharma's average Total Assets over the quarter that ended in Mar. 2025 was ₹156,776 Mil. Therefore, Piramal Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 45.90%.

Piramal Pharma Gross-Profit-to-Asset % Historical Data

The historical data trend for Piramal Pharma's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Piramal Pharma Gross-Profit-to-Asset % Chart

Piramal Pharma Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Mar25

Gross-Profit-to-Asset %

40.87

29.52

34.97

38.20

Piramal Pharma Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Gross-Profit-to-Asset %	Get a 7-Day Free Trial											40.18	33.35	37.93	36.70	45.90

Competitive Comparison of Piramal Pharma's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Piramal Pharma's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Piramal Pharma's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Piramal Pharma Gross-Profit-to-Asset % Calculation

Piramal Pharma's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Mar. 2025 )	/	( (Total Assets (A: Mar. 2024 )	+	Total Assets (A: Mar. 2025 ))	/ count )
	=	59195.3	/	( (153118.1	+	156775.9)	/ 2 )
	=	59195.3	/	154947
	=	38.20 %

Piramal Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2025 )	/	( (Total Assets (Q: Dec. 2024 )	+	Total Assets (Q: Mar. 2025 ))	/ count )
	=	71963.6	/	( (0	+	156775.9)	/ 1 )
	=	71963.6	/	156775.9
	=	45.90 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Piramal Pharma Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Piramal Pharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Piramal Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (BOM:543635) » Definitions » Gross-Profit-to-Asset %

Traded in Other Exchanges

PPLPHARMA:India

Address

Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070

Website

https://www.piramalpharma.com

Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.

Piramal Pharma Headlines

No Headlines